Assessing Primary Non-Adherence for Newer Glucose Lowering Medications for Patients with Type 2 Diabetes

PI(s): Jing Luo, MD, MPH

Project Summary: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are newer glucose lowering medications approved for the treatment of type 2 diabetes. Studies describing the patterns of selection, electronic prescribing and filling (medication adherence) of GLP1-RA and SGLT2i’s are extremely limited. Furthermore, the prevalence of primary non-adherence to these classes have not been previously described. This study’s goal is to measure primary non-adherence to GLP1-RA and SGLT2i for patients enrolled in a UPMC health plan by using EHR and health plan data.

Goal(s): To measure primary non-adherence to GLP1-RA and SGLT2i for patients enrolled in a UPMC health plan.

Study Design: Retrospective cohort study

PaTH Partners:

• UPMC/UPMC Health Plan
• University of Pittsburgh

Sponsor: PCORI®, NIH/NCATS